Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686027 | 0.89 | PDE7A (0.35) | KMT2ALMNASMN1; SMN2CYP1A2PDE4A | |
| SCHEMBL7678955 | 0.79 | LMNA (0.38) | LMNASMN1; SMN2CYP1A2PDE4ACYP2C19 | |
| SCHEMBL7686214 | 0.78 | SREBF2 (0.30) | — | |
| SCHEMBL7682858 | 0.78 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL7680919 | 0.70 | KDM4E (0.40) | KMT2A | |
| SCHEMBL7677294 | 0.67 | PRKCI (0.44) | KMT2ALMNA | |
| SCHEMBL7681091 | 0.67 | MEN1 (0.33) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7685581 | 0.67 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL7679236 | 0.65 | PDE4B (0.37) | — | |
| SCHEMBL2920664 | 0.65 | PRKCI (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | KMT2A 948/4885LMNA 1397/4885SMN1; SMN2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.